StratiCELL Smart science dedicated to healthcare

Created in 2005 and based on a team of 14 people, StratiCELL is a leader in creative, innovative solutions for in vitro objectification. Its goal: to use its skin biology know-how to benefit scientific innovation in dermatology and dermo-cosmetics.

Through a continuous R&D process and market presence over the past 15 years, StratiCELL has developed over 200 tests/biomarkers that allow in vitro objectification of molecules, extracts and products for cosmetic purposes and pre-clinical studies. In this way, StratiCELL allows the producers of therapeutic active substances or compounds to objectify the performance efficiency claims of their products using scientific data. These tests are in particular based on monolayer skin cultures and on 3D skin models reconstructed via tissue engineering: cultivated on a porous polycarbonate membrane, the cells of the epidermis (or keratinocytes) stand out and form a stratified structure that is characteristic of the epidermis. The integration of other cell types such as pigment cells (or melanocytes), fibroblasts of the dermis, sensitive neurons etc. allow for the modelling of a number of pathologies such as atopic eczema, psoriasis, itching, age spots and skin ageing – a technology that positions StratiCELL as one of the European leaders when it comes to in vitro objectification studies. StratiCELL's activities are based on a continuous innovation process aimed at the constant production of new ideas, new technical approaches and new models and tests in line with market trends: skin microbiome, protection of the skin against polluting stresses, pigmentation defects such as age spots, inflammatory diseases linked to atopy or psoriasis etc. This desire for innovation meets demand from over 200 customers, including some of the largest names in the cosmetics and dermo-pharmaceutical industry along with smaller structures active in the development of plant-, algae- or synthetic-based compounds. development of new reconstructed skin models that integrate components from the peripheral nervous system and immune system, with a view to modelling the sensory aspects of skin and inflammatory pathologies such as psoriasis and atopy. StratiCELL also supplies its tissue engineering expertise to MICROBIOS, another project supported by the Walloon Region for the period 2019-2022 with a view to modelling interactions between skin and its microbiota by integrating a microbiological component into in vitro skin models. It is a matter of proposing totally innovative approaches to assess the effect of active substances or extracts on the bacterial ecosystem and identify the therapeutic compounds in pathologies linked to a microbial flora imbalance such as acne, dermatitis, body odour, dandruff or fungal infections. StratiCELL also invests heavily on own funds to set up functional tests for instance on human sebocytes and sensitive neurones, both derived from iPSC pluripotent stem cell reprogramming technology. StratiCELL also intends to develop in the very near future innovative skin models for the evaluation of compounds for veterinary use. These promising prospects have given StratiCELL a desire to explore the potential of the US market. In its sights is the goal of opening of a representative office or the creation of a local subsidiary. This would reinforce its position as leader. Dr Michel Salmon, founder and CEO, StratiCELL © StratiCELL

Enjoying such high recognition, StratiCELL mainly bases its development strategy on a policy of omnipresent innovation: the company is intensifying its efforts dedicated to R&D into new trial models in the area of skin biology via investments on own funds and projects (whether collaborative or otherwise). To this end, the IMPROVE project, supported by the Walloon Region, allows for the

StratiCELL Science Park Crealys Rue Jean Sonet 10 - B-5032 Les Isnes Tel.: +32 (0)81 72 85 82 E-mail: info@StratiCELL.com https://www.StratiCELL.com/